BRISTOL MYERS SQUIBB

The FDA is set to share results on Bristol Myers Squibb’s KarXT for schizophrenia, which targets muscarinic receptors. KarXT, a combination of xanomeline and trospium, shows potential as a breakthrough treatment with a unique mechanism and fewer adverse effects. The approval could lead to further innovations in schizophrenia treatment, aiming for safer, more effective, and easier-to-use medications.

Bristol Myers Squibb awaits FDA decision on KarXT, a novel schizophrenia treatment potentially representing the first new approach in decades. KarXT, acquired via $14 billion deal with Karuna Therapeutics, targets M1 and M4 muscarinic receptors, offering efficacy without antipsychotic side effects. Other companies, including Neurocrine Biosciences, AbbVie, Reviva Pharmaceuticals, Boehringer Ingelheim, and Alto Neuroscience, are also developing schizophrenia treatments, focusing on various mechanisms to address positive, negative, and cognitive symptoms.

VerImmune Inc. secures $4.5 million in Pre-Series A financing, led by Beiley Biofund, to advance its Virus-inspired Particle (ViP™) platform technology. The funding will support the development of VERI-101, a first-in-class cancer immunotherapy, and expand strategic partnerships. The company also adds Dr. Che Hsu and Dr. Marta New to its Board of Directors.

PM Modi held a 'fruitful' roundtable with US tech CEOs in NY, discussing AI, quantum, biotech, computing, and semiconductors. He emphasized India's growth prospects, IP protection, and fostering tech innovation, aiming to make India a global hub for semiconductor manufacturing and a biotech powerhouse.

Prime Minister Modi interacted with tech CEOs in New York, focusing on AI, Quantum, Biotechnology, Computing, and Semiconductors. He emphasized India's commitment to becoming a global tech hub and protecting intellectual property, encouraging collaboration and innovation.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.

A 10-year follow-up of the CheckMate 067 trial showed that 50% of metastatic melanoma patients treated with nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, with no new safety signals identified.

Isatuximab-irfc (Sarclisa) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) received FDA approval for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. The approval is based on the phase 3 IMROZ trial, which showed a 40% reduction in disease progression risk and superior progression-free survival compared to VRd alone.

Amgen's recent launches, like Lumakras, have underperformed, but the $28B Horizon acquisition could boost Tepezza sales. MariTide, in phase 2 for weight loss, shows promise. Amgen's pipeline includes over 30 phase 3 programs, aiming for label expansions and biosimilars. Despite recent slow organic growth, Tezspire's success and upcoming approvals suggest future growth. Amgen offers a 2.68% forward yield, making it a reliable dividend stock.